Eurocord data management activity: data fl ow between Eurocord, cord blood banks,transplant centers and EBMT. On behalf of Eurocord Registry-ABM and Eurocord Study Offi ce C.
Austrian transplant centers (TC) send in MED-A reports on all transplants quarterly due to national competent authority requirements. We analyzed the quality of data reported to the Austrian Stem Cell Transplantation Registry (ASCTR) from 2000 to 2011 regarding diagnosis and disease status. Main diagnosis was reported in 100% of transplants (n=4766). According to subclassifi cations of main transplant indications, 0.9 % of overall lymphomas (n = 1061), 3% of B-cell lymphomas (n=703), 87% of diff use large B-cell lymphomas (n=336) and 7% of T-cell lymphomas (n=123) were not further specifi ed. Only 0.4% solid tumors (ST, n = 498) miss a subclassifi cation. For acute leukemia (AL, n = 1078) diff erentiation into AML, ALL and others was available in all patients. Two and 5% of primary AMLs (n = 610) and ALLs (n= 344) are without further subclassifi cation. In plasma cell disorders (PCD, n = 1425) subdivision into myeloma (MM) and other types is complete. Within MM (n=1383) information on light chain only, or heavy and light chain is missing in 0.4% whereas in 17% of patients with heavy and/or light chain MM the distinction between λ or κ is missing. Chronic leukemias (CL, n=203) had complete information on the subcategories chronic myeloid leukemia (CML, n=137), chronic lymphocytic leukemia (CLL, n=63) and chronic prolymphocytic leukemia (CPL, n=3). However, in CLL 12% had no further subclassifi cation. Then, we analyzed the reporting of disease status at transplant (n=4554) for the above mentioned indications plus for secondary AL, myelodysplastic syndrome, myeloproliferative neoplasms (sAL/MDS/MPN). On average in 3% this information is missing with a range from 0.7% (AL) to 10% (ST). Regarding best response data after transplant 18% (sAL/MDS/MPN) to 30% (ST) are missing. Information on disease status at last reported followup (FU) for patients reported 'alive' and having a FU > 100 days (n= 2154) is missing in 35%, showing a remarkable range from 17% (sAL/MDS/MPN) to 86% (CL). Summary: There are reporting diff erences between disease groups which need detailed investigation. Further eff orts are necessary to achieve complete best response and disease status data at FU in all patients. Support to transplant centers reporting a constantly growing number of patients is warranted to improve quality. We would like to thank all individuals providing data to the ASCTR and colleagues in the EBMT data offi ces for their support.
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How we improved the data quality management of PROMISE in our hospital E. Marin, S. Chantepie, A.C. Gac, V. Moreno, S. Desvoye, N. Kientz, O. Reman CHU Caen (Caen, FR) As others centers in Europe, our data concerning transplants realized in our unit are introduced on Promise registry. Improving the quality of these data is crucial for two major reasons: -1) these data allow retrospective studies which are the basis of our clinical experience as in French registry (SFGM-TC) or European registry (EBMT).
-2) these data are not controlled by the EBMT organization. This explains why JACIE quality program suggests checking some items. We report our procedure which seems for us quite safe and gives some benefi ce in the medical control of the data and moreover improving the quality of communication of results to the whole staff of our unit. Bone marrow transplant unit center organization. Our transplant unit staff comprises the head of the unit (MD), an assistant (MD), a nurse coordinator, a medical secretary and a data manager. On your center, data manager is in charge of compilation of initial and updating data in Promise. The entire process is described below. Print from EMBT site « www.ebmt.org » update paper form, data collection at timepoint Day100 and Day 365 for each transplant by data manager with medical fi le:Data collection in real time by competent staff in HSCT. MEDB form reviewed by unit manager with a data manager interview and medical fi le: Medical doctor data validation. Then regitration done after correction and/or additional data requested. Registration on local base with patient's identifi cation and corresponding UPN number allocation by promise software. Data presentation at the regional multidisciplinary meeting every month:Communication At the end on annual year, the paper record is kept with central archive system procedure validation by program director and quality directory department:Data tracking system Discussion The JACIE program director validated this data management process which is registered in documentation software of the hospital. We have begun this process one year ago and we have to manage two points yet: -how to improve the long term data follow up on graft late eff ect -evaluate the percentage of errors in conducting audits of these items. However, we can already confi rm the completeness of our fi rst year graft data, the improving communication of these results to our staff . In conclusion, the development of quality management as the enhancement of the quality of PROMISE registry needs motivation, tenacity and gives some satisfaction even if it is time-consuming eff ort.
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accreditation. During the last 20 years the Eurocord-Netcord and NMDP collaborate to provide the most suitable and high quality CBU for patients. Eurocord analyses CBT outcomes and proposes guidelines for donor selection. Currently, more than 9600 CBT have been registered. CBT have been performed since 1988 in more than 50 countries and 570 transplant centers (TC) worldwide, mostly EBMT centers (75%). Since 2010, the Eurocord Registry (ER) is hosted by the Agence de la Biomédecine (ABM), a French public administrative institution, competent in organ, tissues and cell donation and transplantation. The main mission of ER is to provide validated clinical CBT outcome data for quality control of CBU transplanted. Once a CBU is shipped, every CBB/donor registry that signed an agreement with ABM sends specifi c shipment forms to the ER. These forms include CBU characteristics, such as HLA typing, TNC/CD34+ cell dose, methods of processing and characteristics of the patients and diseases. The information is captured in the ER database after validation. The ER provides an annual activity report to CBB and registries to ensure quality control of the CBU. ER sends reports to the Eurocord study offi ce to be used in clinical research. Once a CBT is performed, EBMT-TC reports information on patient, CBT and outcome to EBMT database via Promise. In case the data is not yet registered in Promise, ER-contacts the TC to collect data directly. ER informs EBMT about modifi cations confi rmed by TC. The Eurocord study offi ce is located in Saint Louis Hospital and is in charge of the observational clinical studies to evaluate the results of CBT in various diseases, in collaboration with the EBMT Working Parties (WP). Once a study is proposed and approved, the study synopsis and specifi c questionnaire are sent to each TC principal investigators (PI). Eurocord study data managers contact the TC-PI and encourage them to register the required information in the EBMT database via Promise. The retrieved data is updated in the ER database after verifi cation for accuracy and consistency. The synergic work between ER, Eurocord study offi ce, EBMT and TC leads to an accurate database and an effi cient high quality data management system, which allow reliable CBT studies.
P1432 Overall survival (OS) after bone marrow transplantation (BMT) for acute myeloid leukaemia (AML) patients using reduced intensity or myeloablative conditioning regimens; comparison of two methods to control confounding L. Rheingold, O. Paltiel, B. Avni, A. Matusevitch, M. Shapira, R. Or, I. Resnick Hadassah University Medical Center (Jerusalem, IL)
Objective: Propensity score matching (PSM) is used to generate groups with a similar distribution of covariates, therebyreducing confounding in retrospective analyses comparing treatment approaches.
Here we apply PSM to analyze OS in AML patients after T-cell repleted transplants and two types of conditioning regimens.
Methods and materials: We analyzed survival of 382 AML patients, transplanted between 1981 and 2011, who received myeloablative (MA, n=282) or reduced intensity conditioning (RIC, n=100) regimens prior to transplant. A PS was generated through binary regression and pair matching using the greedy procedure syntax and macros. We compared the results with a univariate Kaplan Meier (KM) method and standard Cox multivariate analysis using SPSS 20.0; MS Excel.Factors included in the PSM procedure and Cox model were protocol type (MA vs. RIC) as a predictor variable; and age groups, diagnosis (AML vs. AML/MDS), disease stage (CR1 or later), cytogenetics/molecular fi ndings, donor/patient ABO-, CMV-, and sex-matching, TBI containing vs. TBI free regimen, and presence/absence of acute graft versus host disease as covariates. Results: Univariate KM analysis did not demonstrate signifi cant diff erences in OS between patients transplanted using MA or RIC conditioning (p=0.832) for all AML stages. Multivariate Cox analysis revealed that disease stage was independently associated with OS (any CR vs. active disease (p=0.027, HR=0.515 CR95% 0.286-0.927), but showed no signifi cant eff ect of the conditioning regimen (p=0.439). The PSM procedure generated 11 matched pairs of patients for each comparison. The proportion of the variance in OS explained by the variables matched in the PS, assessed by Nagelkerke`s R2 was 0.452, indicating a moderate relationship between the covariates used for matching and the prediction of OS. Comparison of OS for pairs using the KM method after PSM (p=0.551) showed similar results for RIC and MA as did the standard analysis ( Figure) . Summary: OS analysis after PSM showed similar results to standard multivariate survival analysis after adjustment for confounders. In single center studies, which consist of hundreds of subjects, the quality of matching is suboptimal, which leads to a reduction of power to assess diff erences between the groups, while maintaining the pattern of the overall trends. PSM is more appropriate when the pool of available subjects is very large, as in registrybased studies.
P1433
Loss to follow-up as competing event in ECP treatment of cGvHD L. Scudeller, C. Del Fante, G. Viarengo, M. Cervio, C. Perotti Fondazione IRCCS Policlinico San Matteo (Pavia, IT) Objectives: Competing-risk survival analysis is recommended in several settings, particularly in onco-haematology. Loss to follow-up (LTFU) is always diffi cult to take into account, for several reasons: for instance, patients referred to highly specialized Centres from distant sites may simply not attend follow-up visits for purely logistic reasons, in case of good outcome. Also, in many settings, limited sample size do not allow sophisticated analyses. We explore the eff ect of diff erent ways of including LTFU in competing-risk models among a cohort of patients undergoing
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extracorporeal photopheresis (ECP) for cGvHD, in the estimates of ECP-specifi c survival according to a single predictor (response to ECP). Methods: A dataset of 102 patients with cGvHD treated with ECP was used (Transfusion 2012; 52(9):2007-15 Table. Cumulative hazard of death in with/out LTFU as competing event (scenario 1a vs 2 vs 3a) is reported in Figure. Conclusion: LTFU were frequent. Cumulative hazard of death is underestimated if competing risk of LTFU is not taken into account. In this specifi c setting, relative risk of response to ECP on survival was not diff erent in competing risk models taking into account LTFU, which however were more effi cient. Exceedingly pessimistic assumptions (e.g. LTFU=dead) lead to underestimate of relative risk. It is probable that the small sample size limited the possibility of fi ner modelling.
